Federated Hermes
CCCC icon

Federated Hermes’s C4 Therapeutics CCCC Stock Holding History

Federated Hermes’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.94K Buy
+1,878
New +$4.42K ﹤0.01% 1893
2025
Q2 		– Sell
-1,069
Closed -$1.71K – 2077
2025
Q1 		$1.71K Buy
+1,069
New +$3.19K ﹤0.01% 1961
2024
Q3 		– Sell
-316
Closed -$1.46K – 2070
2024
Q2 		$1.46K Buy
+316
New +$1.89K ﹤0.01% 1922
2023
Q4 		– Sell
-3,141
Closed -$5.84K – 2061
2023
Q3 		$5.84K Buy
3,141
+2,739
+681% +$8.35K ﹤0.01% 1872
2023
Q2 		$1.11K Sell
402
-3,055
-88% -$9.82K ﹤0.01% 2025
2023
Q1 		$10.9K Sell
3,457
-7,614
-69% -$44.8K ﹤0.01% 1866
2022
Q4 		$65.3K Buy
11,071
+10,076
+1,013% +$83.5K ﹤0.01% 1689
2022
Q3 		$9K Buy
+995
New +$10.3K ﹤0.01% 1840
2022
Q1 		– Sell
-41,897
Closed -$1.35M – 2209
2021
Q4 		$1.35M Sell
41,897
-16,715
-29% -$661K ﹤0.01% 1166
2021
Q3 		$2.62M Buy
+58,612
New +$2.51M 0.01% 974
2021
Q2 		– Sell
-38,975
Closed -$1.44M – 2218
2021
Q1 		$1.44M Buy
+38,975
New +$1.55M ﹤0.01% 1237

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes's CCCC Position: Q1 2026 in Review

Federated Hermes opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 1,878 shares worth $4.94K. The stake represents ﹤0.01% of the portfolio and ranks #1893 among its holdings. This is a return to the name: Federated Hermes previously reported a position in CCCC as recently as Q1 2025.

Federated Hermes first reported a position in CCCC in Q1 2021 and has held it in 11 quarters since. The position peaked at $2.62M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Federated Hermes held 1,878 shares of C4 Therapeutics worth $4.94K as of Q1 2026.
  • C4 Therapeutics was a new Federated Hermes position in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1893 holding.
  • Federated Hermes first reported a position in C4 Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Federated Hermes's C4 Therapeutics position peaked at $2.62M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.